Alnylam Pharmaceuticals
ALNY
443 hedge funds and large institutions have $18.6B invested in Alnylam Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 155 increasing their positions, 149 reducing their positions, and 56 closing their positions.
21% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 56
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
2% more funds holding
Funds holding: 433 → 443 (+10)
1.13% more ownership
Funds ownership: 93.7% → 94.83% (+1.1%)
4% more repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 149
0% less capital invested
Capital invested by funds: $18.6B → $18.6B (-$36.4M)
28% less call options, than puts
Call options by funds: $143M | Put options by funds: $199M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$865M |
| 2 |
Amundi
Paris,
France
|
+$94.6M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$70.6M |
| 4 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$40.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$39.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$289M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$168M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$155M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$72.7M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$62.7M |
ALNY Hedge Fund Activity: Q1 2022 in Review
443 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2022, worth a combined $18.6B — down 0.2% from $18.6B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new ALNY positions and 56 closed out — a net gain of 12 holders — while 155 added to existing stakes and 149 trimmed.
The largest buyer was Capital World Investors, adding an estimated $865M. The largest seller was Fidelity Investments, cutting an estimated $289M.
- 443 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2022, up from 433 in Q4 2021.
- Funds reported $18.6B of Alnylam Pharmaceuticals stock for Q1 2022, down 0.2% quarter-over-quarter.
- 68 funds opened new Alnylam Pharmaceuticals positions in Q1 2022 and 56 closed out, a net change of +12 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2022 was Capital World Investors, an estimated $865M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2022 was Fidelity Investments, an estimated $289M sold.
Based on aggregated 13F filings for Q1 2022.